Compare NTNX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTNX | JAZZ |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 10.4B |
| IPO Year | 2015 | 2007 |
| Metric | NTNX | JAZZ |
|---|---|---|
| Price | $39.29 | $178.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $64.33 | ★ $215.92 |
| AVG Volume (30 Days) | ★ 4.2M | 974.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 227.45 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,537,927,000.00 | $1,618,693,000.00 |
| Revenue This Year | $13.91 | $6.17 |
| Revenue Next Year | $13.28 | $7.66 |
| P/E Ratio | $68.49 | ★ N/A |
| Revenue Growth | ★ 18.11 | N/A |
| 52 Week Low | $35.39 | $95.49 |
| 52 Week High | $83.36 | $198.00 |
| Indicator | NTNX | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 50.46 |
| Support Level | $35.84 | $176.67 |
| Resistance Level | $42.63 | $182.99 |
| Average True Range (ATR) | 1.76 | 6.39 |
| MACD | 0.19 | -0.90 |
| Stochastic Oscillator | 48.20 | 28.45 |
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.